Covid-19 remains an overhang on the near-term growth outlook of Asia and lockdown measures are constraining consumption growth, Morgan Stanley said on Friday.Strength in exports and capex has lifted Asia's overall GDP closer to its pre-Covid path, but consumption remains below its pre-Covid path, it said in a research report titled 'The Viewpoint: The Next Phase in Asia's Recovery' authored by Chetan Ahya, Derrick Y Kam and Jonathan Cheung.However, the report forecast vaccination rates for adult population reaching 80 per cent or higher in 10 out of 12 economies (accounting for 95 per cent of the region's GDP) in the region by 4Q21."These high rates of vaccinations will allow policymakers to shift their Covid management strategy and allow restrictions to be relaxed, which we expect in turn lead to a full-fledged recovery in growth from early next year."Powered by all its engines, said the report, Asia's growth momentum should improve in the coming quarters. GDP levels will exceed ...
Sequentially, combined net profit down 12.4%, net sales by 7.8%
Here's an insight into the June quarter performance of some of India's key sectors and companies therein
Mining major Coal India suffered losses to the tune of Rs 700 crore in the April-June quarter owing to a sharp rise in diesel prices, a top company official said
The company says it continues to incur various costs owing to the grounding and the inability of Boeing 737 Max aircraft to undertake revenue operations
The stock of the pharmaceutical company was trading at its lowest level since June 2020
The adverse impact of inflation and higher commodity prices is visible in the overall corporate results for Q1FY22
It is up 15% since the start of CY21 against 19% in Nifty50; this despite banks' record Q1 profit
SFBs - AU, Ujjivan, Equitas, and Suryoday - reported a combined net loss of Rs 66 crore in the June quarter of financial year 2021-22
Shares of SpiceJet on Monday declined by more than 4 per cent at close after the company reported a loss of Rs 729 crore for the April-June quarter
In its note ICICI Securities said it sees 'high risk and huge concern for VIL' and it has put VIL's estimates, rating and target price under review until further clarity
The advance-decline ratio remained skewed in favour of seller, highlighting underlying bearishness in market.
In the past six months, the stock has zoomed 120 per cent, as compared to a 6.8 per cent rise in the S&P BSE Sensex
The company underperformed peers in the June quarter
Vodafone Idea Q1 Preview: Voda Idea's fundraising plans and commentary on average revenue per user (ARPU) trajectory ahead will remain key monitorables for experts and investors alike
Dewan Housing Finance Corporation (DHFL) on Friday reported an over four-fold jump in its consolidated net profit at Rs 314.43 crore for the quarter ended June 2021. The company had posted a net profit of Rs 70.10 crore in the same quarter a year ago and Rs 96.75 crore in the preceding quarter ended March 2021. The total income, however, fell by 14 per cent to Rs 2,001.36 crore during Q1 FY22, as against Rs 2,328.86 crore in Q1 FY21 as interest income fell, DHFL said in a regulatory filing. Interest earned in the June 2021 quarter fell to Rs 1,990.72 crore, as against Rs 2,315.93 crore earlier. On the other hand, expenses reduced drastically to Rs 1,553.74 crore from Rs 2,236.05 crore. The National Company Law Tribunal (Mumbai bench) had in June this year approved the resolution plan submitted by Piramal Capital & Housing Finance for the debt-ridden DHFL. Subsequently, the company set up a monitoring committee in July, as per the terms of the resolution plan and the plan approval
State-owned construction firm NBCC on Friday reported an over three-fold jump in its consolidated net profit at Rs 37.07 crore for the quarter ended June
Glenmark Pharmaceuticals on Friday said its consolidated profit after tax (PAT) increased by 21 per cent to Rs 306 crore for the first quarter ended June 30. The Mumbai-based drug major had reported a PAT of Rs 254 crore in the April-June quarter of the 2020-21 fiscal. The company's consolidated revenue rose to Rs 2,965 crore from Rs 2,345 crore in the Q1 of last fiscal. "It was a landmark quarter for the company with positive momentum in all our key markets. Our commitment towards the fight against COVID-19 was reflected in FabiFlu becoming the number one brand in the India pharma market in April. "We launched our first nebuliser, Arformoterol Inhalation solution from Monroe, US," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said in a statement. The company has a strategic roadmap to grow consistently and profitably over the year, he added. "We have a clear plan in place to reduce debt by enhancing free cash, prioritising over R&D investments and capita
Consolidated total income rose to Rs 1,09,301.82 crore, up from Rs 63,694.14 crore last year
Most analysts remain bullish on the stock